JUSTIN REMSING: Open Payments
NPI 1376970905 · FARMINGTON HILLS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,976 in 110 payments from 18 companies in 2025. Trend: 2023 $242 · 2024 $1,699 · 2025 $1,976
Food & beverage: $1,976
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $258 |
| Neurocrine BioSciences, Inc. | 4 | $192 |
| Vanda Pharmaceuticals Inc. | 9 | $175 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $169 |
| ABBVIE INC. | 13 | $168 |
| Corium, LLC | 7 | $134 |
| Collegium Pharmaceutical, Inc. | 5 | $119 |
| Alkermes, Inc. | 6 | $115 |
| Supernus Pharmaceuticals, Inc. | 6 | $109 |
| Lundbeck LLC | 4 | $82 |
Products named: REXULTI, INGREZZA, FANAPT, CAPLYTA, VRAYLAR, Azstarys, Jornay PM, Qelbree.
Industry payments across MI — which companies pay providers there.
